AI Summary & Key Takeaways
AI InsightTreatment of gouty arthritis in patients with renal disease is a challenging task, because the useof non-steroidal anti-inflammatory drugs as well as colchicine requires special care and lower doses of allopurinol shouldbe administered.
📌 3 Key Takeaways
Özet
Uric acid is the final product of purine metabolism. Hyperuricemia may result from increased production or reduced excretion of uric acid. Hyperuricemia represents a risk for gouty arthritis. In this condition, monosodium urate (MSU) crystalsreach a concentration above the solubility threshold and lead to gouty arthritis after precipitation in the joints. Gouty arthritis is the most common type of inflammatory arthritis in adults. On the other hand, chronic renal disease has becomea global public health problem associated with increased morbidity and mortality. Elevated serum uric acid is a commonfinding in patients with chronic kidney disease. Furthermore, chronic kidney disease represents the most common andindependent risk factor for gouty arthritis. Patients with gouty arthritis have an increased prevalence of chronic kidney disease. Gouty arthritis is a potentially treatable condition. Therapeutic options include non-pharmacological (education andnutritional counseling) and pharmacological (non-steroidal anti-inflammatory drugs, glucocorticoids, colchicine, and IL-1antagonists) approaches. Treatment of gouty arthritis in patients with renal disease is a challenging task, because the useof non-steroidal anti-inflammatory drugs as well as colchicine requires special care and lower doses of allopurinol shouldbe administered.